Detalles de la búsqueda
1.
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
BMC Cancer
; 24(1): 252, 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38395832
2.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281295
3.
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric Cancer
; 27(3): 558-570, 2024 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38308771
4.
Sex-dependent different clinicopathological characterization of Epstein-Barr virus-associated gastric carcinoma: a large-scale study.
Gastric Cancer
; 27(2): 221-234, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212543
5.
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Cancer
; 129(19): 2966-2974, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37246414
6.
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Oncologist
; 28(9): e823-e834, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37036671
7.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37919668
8.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36814222
9.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
; 37(4): 176-183, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37104758
10.
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Jpn J Clin Oncol
; 53(3): 221-229, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36533429
11.
The Hospitalist-Oncologist co-ManagemEnt (HOME) system improves hospitalization outcomes of patients with cancer.
BMC Health Serv Res
; 23(1): 1367, 2023 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38057800
12.
Protective Effects of PEP-1-GSTA2 Protein in Hippocampal Neuronal Cell Damage Induced by Oxidative Stress.
Int J Mol Sci
; 24(3)2023 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36769090
13.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
; 23(11): 1430-1440, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36244398
14.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(2): 234-247, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35030335
15.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Lancet Oncol
; 23(12): 1558-1570, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36400106
16.
Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Ann Surg Oncol
; 29(8): 5084-5091, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322307
17.
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Gastric Cancer
; 25(3): 609-618, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015188
18.
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer
; 25(1): 207-217, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480657
19.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34793719
20.
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Cancer Sci
; 112(11): 4669-4678, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327766